Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHIVANG G JOSHI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1902034531
CMS profile
40155
Location
WESTBOROUGH, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$87,220.58

185 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $39,821.99 73
Eli Lilly and Company $18,982.62 16
IMPEL PHARMACEUTICALS INC. $17,857.95 27
H. Lundbeck A S $4,664.25 7
Lundbeck LLC $3,783.99 11
PFIZER INC. $1,243.86 23
UPSHER-SMITH LABORATORIES LLC $338.51 5
Teva Pharmaceuticals USA, Inc. $286.50 8
Lilly USA, LLC $120.88 9
Amgen Inc. $43.01 2
ACADIA Pharmaceuticals Inc $23.34 1
Amneal Pharmaceuticals LLC $19.80 1
Acorda Therapeutics, Inc $19.63 1
Eisai Inc. $14.25 1

Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHIVANG G JOSHI

NPI 1902034531 · CMS profile ID 40155

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

WESTBOROUGH, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902034531?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHIVANG G JOSHI, NPI 1902034531, CMS profile ID 40155. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902034531?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SHIVANG G JOSHI, NPI 1902034531, CMS profile ID 40155. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902034531?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SHIVANG G JOSHI, NPI 1902034531, CMS profile ID 40155, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1902034531?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

185 matching records · $87,220.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 185 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–185 of 185.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $479.2403/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584813 CMS
IMPEL PHARMACEUTICALS INC. $3,976.0003/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989395895 CMS
Teva Pharmaceuticals USA, Inc. $31.9603/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056738223 CMS
ABBVIE INC. $19.7603/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584811 CMS
IMPEL PHARMACEUTICALS INC. $90.5703/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989395929 CMS
IMPEL PHARMACEUTICALS INC. $1,154.8203/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989396047 CMS
PFIZER INC. $21.5003/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049121277 CMS
IMPEL PHARMACEUTICALS INC. $1,600.0003/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989396053 CMS
Lundbeck LLC $22.4803/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032254009 CMS
Lundbeck LLC $124.7703/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032254015 CMS
Eli Lilly and Company $2,100.0003/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032394525 CMS
ABBVIE INC. $17.7303/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584809 CMS
IMPEL PHARMACEUTICALS INC. $4.5203/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989395949 CMS
ABBVIE INC. $3,000.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584807 CMS
UPSHER-SMITH LABORATORIES LLC $55.2102/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 994138445 CMS
Amneal Pharmaceuticals LLC $19.8002/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053503811 CMS
ABBVIE INC. $3.9402/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584805 CMS
Lilly USA, LLC $13.6302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032348857 CMS
PFIZER INC. $22.1402/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050529591 CMS
ABBVIE INC. $11.5002/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584803 CMS
Lundbeck LLC $4.3802/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032253991 CMS
Lundbeck LLC $22.2902/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032253997 CMS
Lundbeck LLC $5.7102/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032254003 CMS
ABBVIE INC. $21.8002/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584801 CMS
Teva Pharmaceuticals USA, Inc. $29.9602/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056738165 CMS
UPSHER-SMITH LABORATORIES LLC $80.5501/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 994136023 CMS
ABBVIE INC. $96.2301/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584799 CMS
PFIZER INC. $27.3301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050310467 CMS
Acorda Therapeutics, Inc $19.6301/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1005347717 CMS
ABBVIE INC. $6.6701/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584797 CMS
ABBVIE INC. $19.9501/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584795 CMS
ABBVIE INC. $29.3301/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584793 CMS
ABBVIE INC. $5.8601/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997584791 CMS
Lilly USA, LLC $13.8001/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032269645 CMS
IMPEL PHARMACEUTICALS INC. $39.5401/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989395943 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $191,789.02 469
PY2020 $195,504.04 366
PY2021 $250,202.79 537
PY2022 $177,115.80 231
PY2023 $87,220.58 185
PY2024 $96,955.43 162
PY2025 $172,300.47 229

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,980.00 2
PY2025 Principal investigator $200,013.42 92
PY2024 Principal investigator $6,681.14 4
PY2023 Recipient $4,700.00 5
PY2023 Principal investigator $10,967.34 2
PY2022 Principal investigator $77,491.80 6
PY2021 Recipient $15,252.80 2
PY2021 Principal investigator $82,514.36 13
PY2020 Recipient $7,259.50 3
PY2020 Principal investigator $25,134.98 4
PY2019 Principal investigator $51,502.95 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $1,050.00 12/23/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289248
Principal investigator 1 Ipsen Innovation $1,050.00 12/23/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289250
Principal investigator 1 Ipsen Innovation $180.00 12/12/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289252
Principal investigator 1 Merz Pharmaceuticals, LLC $3,733.97 12/10/2025 Non-covered Recipient Entity
MASS INSTITUTE OF CLINICAL RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647426
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289242
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289244
Principal investigator 1 Ipsen Innovation $4,970.00 11/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289246
Recipient PFIZER INC. $780.00 11/18/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727521
Principal investigator 1 Merz Pharmaceuticals, LLC $4,768.05 11/14/2025 Non-covered Recipient Entity
MASS INSTITUTE OF CLINICAL RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647428
Principal investigator 1 Ipsen Innovation $360.00 11/04/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289240
Principal investigator 1 Ipsen Innovation $3,850.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289206
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289208
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289210
Principal investigator 1 Ipsen Innovation $4,970.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289212
Principal investigator 1 Ipsen Innovation $4,900.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289214
Principal investigator 1 Ipsen Innovation $4,970.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289216
Principal investigator 1 Ipsen Innovation $3,850.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289218
Principal investigator 1 Ipsen Innovation $4,970.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289220
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289222
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289224
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289226
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289228
Principal investigator 1 Ipsen Innovation $1,855.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289230
Principal investigator 1 Ipsen Innovation $4,900.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289232
Principal investigator 1 Ipsen Innovation $4,900.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289234
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289236
Principal investigator 1 Ipsen Innovation $1,050.00 10/27/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289238
Principal investigator 1 Ipsen Innovation $150.00 09/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289202
Principal investigator 1 Ipsen Innovation $90.00 09/26/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289204
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/03/2025 Non-covered Recipient Entity
MASS INSTITUTE OF CLINICAL RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647418
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/03/2025 Non-covered Recipient Entity
MASS INSTITUTE OF CLINICAL RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647420
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/03/2025 Non-covered Recipient Entity
MASS INSTITUTE OF CLINICAL RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647422
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/03/2025 Non-covered Recipient Entity
MASS INSTITUTE OF CLINICAL RESEARCH LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647424
Principal investigator 1 Ipsen Innovation $4,900.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289162
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289164
Principal investigator 1 Ipsen Innovation $4,900.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289166
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289168
Principal investigator 1 Ipsen Innovation $4,970.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289170
Principal investigator 1 Ipsen Innovation $10,000.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289172
Principal investigator 1 Ipsen Innovation $3,850.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289176
Principal investigator 1 Ipsen Innovation $2,000.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289178
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289180
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289182
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289184
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289186
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289188
Principal investigator 1 Ipsen Innovation $1,050.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289190
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289194
Principal investigator 1 Ipsen Innovation $1,855.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289196
Principal investigator 1 Ipsen Innovation $1,855.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289198
Principal investigator 1 Ipsen Innovation $4,970.00 08/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289200
Principal investigator 1 Ipsen Innovation $10,000.00 08/14/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289174
Principal investigator 1 Ipsen Innovation $2,000.00 08/14/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289192
Principal investigator 1 Ipsen Innovation $150.00 07/31/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289150
Principal investigator 1 Ipsen Innovation $180.00 07/31/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289152
Principal investigator 1 Ipsen Innovation $600.00 07/31/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289154
Principal investigator 1 Ipsen Innovation $4,970.00 07/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289156
Principal investigator 1 Ipsen Innovation $4,900.00 07/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289158
Principal investigator 1 Ipsen Innovation $175.00 07/28/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289160
Principal investigator 1 Ipsen Innovation $270.00 07/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289146
Principal investigator 1 Ipsen Innovation $300.00 07/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289148
Recipient PFIZER INC. $3,200.00 07/13/2025 Covered Recipient Physician ZAVEGEPANT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727105
Principal investigator 1 Ipsen Innovation $300.00 07/08/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289144
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289106
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289108
Principal investigator 1 Ipsen Innovation $1,855.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289110
Principal investigator 1 Ipsen Innovation $4,900.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289112
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289114
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289116
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289118
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289120
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289122
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289124
Principal investigator 1 Ipsen Innovation $4,970.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289126
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289128
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289130
Principal investigator 1 Ipsen Innovation $1,855.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289132
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289134
Principal investigator 1 Ipsen Innovation $4,900.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289136
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289138
Principal investigator 1 Ipsen Innovation $1,050.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289140
Principal investigator 1 Ipsen Innovation $175.00 06/30/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289142
Principal investigator 1 Ipsen Innovation $90.00 06/16/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289104
Principal investigator 1 Ipsen Innovation $180.00 05/15/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289096
Principal investigator 1 Ipsen Innovation $300.00 05/15/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289098
Principal investigator 1 Ipsen Innovation $300.00 05/15/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289100
Principal investigator 1 Ipsen Innovation $300.00 05/05/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289102
Principal investigator 1 Ipsen Innovation $481.40 04/29/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289094
Principal investigator 1 Ipsen Innovation $450.00 04/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289082
Principal investigator 1 Ipsen Innovation $270.00 04/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289084
Principal investigator 1 Ipsen Innovation $150.00 04/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289086
Principal investigator 1 Ipsen Innovation $180.00 04/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289088
Principal investigator 1 Ipsen Innovation $300.00 04/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289090
Principal investigator 1 Ipsen Innovation $300.00 04/22/2025 Non-covered Recipient Entity
Community Neuroscience Services
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289092

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $5,323.46 1
PY2022 Value of interest $24,983.31 1
PY2021 Amount invested $9,680.04 1
PY2021 Value of interest $19,659.85 1
PY2020 Amount invested $9,979.81 1
PY2020 Value of interest $9,979.81 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

3 records · PY2020–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $5,323.46 $24,983.31 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 962043131
PY2021 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $9,680.04 $19,659.85 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 851043431
PY2020 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $9,979.81 $9,979.81 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 753248529